Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
8.18
0.03 (0.37%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :23,979
Date :05-26-2017
* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at Conferences Next Week

May 18th, 2017|

JERUSALEM, May 18, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that  Chief Executive Officer, Nadav Kidron, will present at […]

Oramed Granted Canadian Patent for GLP-1 Analog Capsule

May 9th, 2017|

JERUSALEM, May 9, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed […]

Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule

May 2nd, 2017|

JERUSALEM, May 2, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that based on positive preclinical data, the Company […]

Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule

April 20th, 2017|

JERUSALEM, April 20, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has granted the […]